EVISA Glossary on | Contact EVISA | Sitemap | Home   
 Advanced search
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).


Supporters of EVISA includes:



Future Medicinal Chemistry


 

Status
active
Subject

Source type
Journal
ISBN ISSN
1756-8919
E ISSN
1756-8927
First volume
1
Last volume
12+
Publish city
London
Homepage
Description

Medicinal chemistry has evolved rapidly into a highly interdisciplinary field, enriched by the collaborative efforts of experts from a wide spectrum of specialist areas, from chemoinformaticians and physical chemists to molecular biologists and pharmacologists. Future Medicinal Chemistry provides a regular point of access to commentary and debate for this ever-expanding and diversifying community. The journal showcases milestones in pharmaceutical R&D and features expert analysis of emerging research-from the identification of targets, through to the discovery, design, synthesis and evaluation of bioactive agents.

There has never been more pressure to produce potent and safe compounds faster and more efficiently. Future Medicinal Chemistry offers a forum for the rapid publication of original research and critical reviews of the latest milestones in the field. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. Where relevant, contributions are also actively encouraged on areas as diverse as biotechnology, enzymology, green chemistry, genomics, immunology, materials science, neglected diseases and orphan drugs, pharmacogenomics, proteomics and toxicology.

Principal themes include:

  • Drug discovery technologies
  • Design and synthesis of novel lead compounds
  • Computational approaches to synthesis and modeling
  • Biophysical techniques for structural characterization
  • Overviews of novel therapeutic strategies and emerging targets
  • Drug targeting and delivery
  • ADME/Tox investigations
  • Commentary on science policy, economic and IP issues

In addition to its core content of Reviews, Patent Reviews, Perspectives and Original Research, the journal also features enlightened commentary and opinion on topical areas of debate relevant to academia and industry, as well as conference reports, interviews and more.

By remaining highly responsive to emerging themes, and providing in-depth analysis of agents of medicinal interest and therapeutic approaches, the journal will act as a valuable reference, not only for medicinal chemists, but for all those interested in the advancement of pharmaceutical science.












Imprint     Disclaimer

© 2003 - 2024 by European Virtual Institute for Speciation Analysis ( EVISA )